TARS at a glance
Tarsus Pharmaceuticals, Inc. (TARS, SEC CIK 1819790) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $451.4 million (up 146.7% from FY2024) and a net loss of $66.4 million. Diluted EPS was -$1.59.
- As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Tarsus Pharmaceuticals, Inc. (TARS) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Azamian Bobak R. on November 13, 2026 of 10,000 shares at $80.31 per share.
- In the last 90 days, TARS insiders reported 0 open-market purchases ($0) and 15 open-market sales ($6.0M) on Form 4, a net sale of $6.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $451.4M
- +146.7% vs prior year
- Insiders · 90 days
- 0 buys · 15 sells
- Net −$6.0M
- 13F holders
- 30 funds
- $1.2B · +1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of therapeutics addressing root causes of eye diseases, beginning with FDA-approved XDEMVY for Demodex blepharitis launched August 2023
- New product emphasis: Advancement of TP-04 for ocular rosacea with Phase 2 trial initiated December 2025; TP-05 oral tablet for Lyme disease prophylaxis with Phase 2 planned for Q2 2026
- Strategic shift: Expanding beyond eye care with systemic prophylactic indication targeting Lyme disease, exploring significant unmet needs outside ophthalmology
- Quantitative highlight: XDEMVY achieved $646 million net product sales launch-to-date; Saturn-2 trial showed 55% complete collarette cure vs 12% vehicle (p<0.0001)
- Noteworthy fact: First FDA-approved therapeutic for Demodex blepharitis with U.S. patient base estimated at 25 million; ongoing global regulatory progress including China approval expected in 2026
Risk Factors
- Risk from OBBB Act tax reform, enacted July 2025, with $2.1M state income tax due to nonconforming states' capitalization requirements
- China geopolitical risk from reliance on China Out-License with $86.1M proceeds and up to $100M sales milestones and royalties exposure
- Supply chain vulnerability from $23.8M non-cancelable minimum XDEMVY manufacturing purchase obligations through 2029
- Commercial disruption risk from expanded direct-to-consumer advertising costs of $112.6M for XDEMVY competing in market
- Financial risk from credit facility with 6.75%+ SOFR interest, $75M drawn in 2024, and potential covenants restricting operations
Management Discussion & Analysis
- Revenue $451.4M full year 2025 from XDEMVY sales, up from zero in 2024, delivering 400,000 bottles in 2025
- Net loss $66.4M in 2025 versus $115.6M in 2024 and $135.9M in 2023, operating expenses to increase with commercial expansion
- Best segment: XDEMVY eye care with $151.7M Q4 sales, ~90% covered lives, gross-to-net discount ~45% annually
- Cash, cash equivalents and marketable securities $417.3M at Dec 31, 2025; funded by IPOs, follow-on offerings, license fees, and credit facilities
- Forward outlook: Phase 2 trials ongoing for TP-04 ocular rosacea (results H1 2027) and TP-05 Lyme prophylaxis (Phase 2 start Q2 2026), potential EU/Japan/China approvals for TP-03
AI summary of the TARS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $194.6M vs $118.7M, up 64% YoY, entirely from XDEMVY product sales
- Gross margin 93% vs 93% YoY; net loss $668.3M vs $12.6M
- XDEMVY best performer: $194.6M sales, up 64% YoY; refills 20% of prescriptions
- Cash, equivalents and marketable securities $309.6M; nine-month operating cash flow $30.6M vs $(31.8)M
- Outlook: Kore and Calliope topline results expected first half 2027; vendor expenses expected to increase during remainder of 2026
Risk Factors
- Newly added acquisition risk: July 6 and September 4, 2026 acquisitions of iRenix and Alkeus created integration and contingent payment exposure
- Most materially updated trade risk: 2026 tariffs could reach 100%, reduced to 20% under a Commerce agreement subject to onshoring compliance
- Regulatory compliance risk: Medicaid, 340B, Medicare, VA and DoD pricing errors could trigger rebates, penalties, False Claims Act liability, or program exclusion
- Near-term operational risk: TP-04 and TP-05 require costly clinical development, with TP-05 Phase 3 needing thousands of patients
- Financial risk: Alkeus carries a potential $250.0 million regulatory milestone payment, payable in cash or common stock
AI summary of the TARS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Tarsus Pharmaceuticals’ third-quarter and nine-month results through September 30, 2026
- Exhibit 99.1 contains the company’s operating results and accompanying financial details
Item EX-99.1: Item EX-99.1
- Q3 product sales $194.6M, up approximately 64% year over year, confirming strong XDEMVY commercial momentum
- XDEMVY surpassed one million bottles dispensed and $1B cumulative net sales since launch
Item EX-99.1: Item EX-99.1
- Alkeus reported audited FY2025 financials, relevant to Tarsus investors because the exhibit appears to provide acquisition-related target disclosures
- Going-concern warning: substantial doubt about Alkeus’s ability to continue operations without additional financing
Item EX-99.2: Item EX-99.2
- Nine-month net loss $35.3M, with operating expenses of $37.0M and no product revenue
- Cash fell to $48.7M from $84.0M, while operating cash burn reached $35.5M
Item EX-99.3: Item EX-99.3
- Alkeus merger closed September 4, 2026, adding gildeuretinol, a late-stage IPR&D asset, but no current revenue
- Tarsus paid preliminary consideration of $585.9M, including $244.6M cash, 2,769,696 shares, and $95.9M contingent liabilities
Item 2.01: Completion of Acquisition or Disposition of Assets
- Acquisition of Alkeus completed September 4, 2026, adding gildeuretinol through a wholly owned subsidiary
- Up-front consideration: $270M cash plus 2,908,692 Tarsus shares, subject to adjustments
Item 8.01: Other Events
- Tarsus completed an acquisition on September 4, 2026
- Transaction completion marks a material strategic change requiring review of Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Acquisition of Alkeus completed, adding worldwide rights to Phase 3 gildeuretinol for Stargardt disease
- Pipeline expands into rare retinal disease with no FDA-approved therapy and estimated 86,000 U.S. patients
AI summaries of TARS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TARS
Don't miss the next TARS filing
- Alerts as it files. A push when TARS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TARS, by share count.
- Ask anything. An AI agent that reads every TARS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Azamian Bobak R. | Sell | Nov 13, 2026 | 10,000 | $80.31 |
| Clase Neera | A | Nov 3, 2026 | 6,678 | - |
| Clase Neera | A | Nov 3, 2026 | 10,587 | - |
| PYOTT DAVID E I | M | Sep 15, 2026 | 201 | - |
| LINK WILLIAM J PHD | M | Sep 15, 2026 | 201 | - |
| PYOTT DAVID E I | M | Sep 15, 2026 | 201 | - |
| LINK WILLIAM J PHD | Sell | Sep 15, 2026 | 759 | $79.00 |
| LINK WILLIAM J PHD | M | Sep 15, 2026 | 201 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $183.0M | $451.4M |
| Operating Income | - | -$120.6M | -$71.0M |
| Net Income | -$135.9M | -$115.6M | -$66.4M |
| Op. Margin | - | -65.9% | -15.7% |
| Net Margin | - | -63.2% | -14.7% |
| Balance Sheet | |||
| Total Assets | $265.5M | $377.0M | $562.2M |
| Equity | - | $224.5M | $343.4M |
| ROE | - | -51.5% | -19.3% |
| Per Share | |||
| EPS | $-4.62 | $-3.07 | $-1.59 |
| Cash Flow | |||
| Operating CF | - | -$83.0M | -$12.5M |
| CapEx | $1.5M | $1.6M | $9.9M |
Source: XBRL data in Tarsus Pharmaceuticals, Inc. (TARS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TARS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 30 | $1.17B |
| Q2 2026 | 29 | $1.02B |
| Q1 2026 | 30 | $1.03B |
| Q4 2025 | 25 | $1.15B |
| Q3 2025 | 28 | $770.7M |
| Q2 2025 | 26 | $547.6M |
| Q1 2025 | 25 | $490.5M |
| Q4 2024 | 20 | $351.2M |
- Two Sigma Investments+147.6K (+410%)
- Invesco Ltd+94.0K (+12%)
- Vanguard Capital Management LLC+85.9K (+5%)
- Goldman Sachs Group+73.5K (+10%)
- Renaissance Technologies LLC+62.8K (+675%)
- Millennium Management−333.3K (-23%)
- Franklin Resources−262.6K (-92%)
- D.E. Shaw & Co−245.5K (-35%)
- Citadel Advisors LLC−132.6K (-55%)
- Morgan Stanley−116.4K (-6%)
- Blackstone Group+3.9K
- M&T Bank+2.6K
- FMR LLC (Fidelity)−672.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 213 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TARS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TARS SEC filings: frequently asked questions
Are TARS insiders buying or selling?
In the last 90 days, Tarsus Pharmaceuticals, Inc. (TARS) officers, directors and 10% owners reported no open-market purchases and 15 open-market sales worth $6.0 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TARS stock?
As of September 30, 2026, the largest Tarsus Pharmaceuticals, Inc. (TARS) holders among the 13F filers tracked by SignalX were BlackRock ($303.9 million), Vanguard Capital Management LLC ($147.7 million), Morgan Stanley ($134.5 million), Bank of America Corp ($92.7 million), State Street Corp ($86.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TARS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $451.4 million (up 146.7% from FY2024) and a net loss of $66.4 million. Diluted EPS was -$1.59. The figures come from the XBRL data in the 10-K.
What are the main risks in TARS's latest 10-K?
In the 10-K filed February 23, 2026, Tarsus Pharmaceuticals, Inc. (TARS) flagged: Risk from OBBB Act tax reform, enacted July 2025, with $2.1M state income tax due to nonconforming states' capitalization requirements. China geopolitical risk from reliance on China Out-License with $86.1M proceeds and up to $100M sales milestones and royalties exposure. (AI summary of the Risk Factors section.)
What did TARS report in its latest 8-K?
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Tarsus Pharmaceuticals’ third-quarter and nine-month results through September 30, 2026.
What are the latest TARS SEC filings?
Tarsus Pharmaceuticals, Inc. (TARS) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 17, 2026.
What is TARS's SEC CIK number?
Tarsus Pharmaceuticals, Inc. (TARS)'s SEC Central Index Key (CIK) is 1819790. EDGAR lists every TARS filing under that number.
Ask anything about TARS
The research agent reads TARS's filings, financials, insider trades and 13F holders, then answers with sources.